in vitro News and Research

RSS

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Researchers develop new method to predict biomaterial's capacity to induce tissue regeneration

Researchers from the Polymer and Advanced Materials Group at the Universitat Jaume I in Castellón have developed an in vitro method to predict the capacity of a biomaterial to induce bone and soft tissue regeneration.

5 Oct 2021

Difficulties of stability and storage of mRNA COVID-19 vaccines

Two researchers have collaborated to review the difficulties faced in storing and transporting these vaccines in a manner that will keep them stable.

4 Oct 2021

Antiviral activity of wheat germ Agglutinin against SARS-CoV-2

A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.

4 Oct 2021

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

The phase 1-2 clinical trials conducted using REGEN-COV had shown promising therapeutic benefits in COVID-19 outpatients. Its effect was further investigated in the present phase 3 clinical trial, the findings of which have been published in the "The New England Journal of Medicine".

3 Oct 2021

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

1 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

EKF Diagnostics appoints Luke Daum as Chief Scientific Officer

EKF Diagnostics, the global in vitro diagnostics company, has appointed Luke Daum PhD as Chief Scientific Officer, bringing a wealth of expertise in molecular-based diagnostics to EKF’s leadership team.

From EKF Diagnostics 1 Oct 2021

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

A team of scientists from the USA and France has recently unveiled the mechanism of immune dysregulation in coronavirus disease 2019 (COVID-19) patients by analyzing the early-stage interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected epithelial cells and immune cells. The study is currently available on the bioRxiv* preprint server.

30 Sep 2021

New drug combination effectively suppresses SARS-CoV-2 infection

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the world.

30 Sep 2021

Novel small-molecule therapy shows promise against deadly pediatric leukemia

Mount Sinai researchers have developed a therapy that shows promise against a deadly pediatric leukemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September.

29 Sep 2021

Novel strategy for in vitro cell-selective protection has potential for use in adoptive cell therapy

Adoptive cell therapy (ACT) is an emerging powerful cancerimmunotherapy, which includes a complex process of genetic modification, stimulation and expansion. During invitroorexvivomanipulation, sensitive cells are inescapably subjected to harmful external stimuli. Although a variety ofcytoprotectionstrategies have been developed, their application on ACT remains challenging.

29 Sep 2021

New analysis reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Oncotarget published "Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells" which reported that to ascertain phenotypical differences between these two distinct culture conditions, these authors carried out a comparative proteomic analysis of a membrane fraction obtained from 3D- and 2D-cultured NSCLC model cell line NCI-H23.

29 Sep 2021

Researchers devise novel technique to count elusive circulating tumor cells

As tumors grow within an organ, they also release cells that enter the bloodstream. These cells can travel to other organs, seeding new tumors called metastases.

29 Sep 2021

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

New findings identify CASP4/11 as detrimental to inflammation and coagulopathy associated with SARS-CoV-2 infection.

28 Sep 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

The findings from this study suggest that HPNs may inhibit viral replication and budding.

27 Sep 2021

SARS-CoV-2 entry inhibitors show antiviral activity

A new study used a combination of a computer-aided drug design approach and cell-based in vitro assays to identify five potential SARS-CoV-2 inhibitors.

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

A team of international scientists has formed a consortium to map the epitope landscape of a range of therapeutic monoclonal antibodies on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the scientists characterized the neutralization potency of these antibodies and have investigated how emerging viral variants with spike mutations can impact antibody-mediated neutralization. They have recently published the consortium findings in the journal Science.

27 Sep 2021